Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NXY-059 in acute ischemic stroke (SAINT I)
NCT00061022Phase 3Completed
- Sponsor
- AstraZeneca
- Start
- May 2003
- Primary completion
- Sep 2006
- Modality
- Small Molecules
- Countries
- 30
01
Overview
Phase 3, randomised, double-blind trial of OKN-007 in ischemic stroke (2 arms), sponsored by AstraZeneca. Primary endpoint: modified Rankin scale at 90 days. Started May 2003; status: completed.
02
Drugs
OKN-007
03
Conditions
ischemic stroke
Beyond the preview
Go deeper on NCT00061022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00061022.